Swiss National Bank Grows Holdings in Merck & Company, Inc. (MRK)

Swiss National Bank raised its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 3.0% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,697,901 shares of the company’s stock after purchasing an additional 307,300 shares during the period. Merck & Company, Inc. accounts for approximately 0.8% of Swiss National Bank’s holdings, making the stock its 22nd biggest position. Swiss National Bank owned 0.39% of Merck & Company, Inc. worth $685,628,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Perennial Advisors LLC boosted its holdings in shares of Merck & Company, Inc. by 10.7% during the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after purchasing an additional 157 shares during the last quarter. Stelac Advisory Services LLC bought a new position in shares of Merck & Company, Inc. in the 2nd quarter valued at about $104,000. Cascade Investment Advisors Inc. lifted its holdings in shares of Merck & Company, Inc. by 15.5% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after acquiring an additional 232 shares during the last quarter. Solaris Asset Management LLC lifted its holdings in shares of Merck & Company, Inc. by 6.3% in the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after acquiring an additional 115 shares during the last quarter. Finally, Harbour Capital Advisors LLC bought a new position in shares of Merck & Company, Inc. in the 1st quarter valued at about $127,000. 72.98% of the stock is owned by institutional investors and hedge funds.

A number of research analysts recently commented on the stock. J P Morgan Chase & Co set a $70.00 price target on shares of Merck & Company, Inc. and gave the company a “buy” rating in a report on Sunday, October 29th. Berenberg Bank reaffirmed a “hold” rating on shares of Merck & Company, Inc. in a report on Wednesday, November 1st. Sanford C. Bernstein reaffirmed a “buy” rating and issued a $64.00 price target on shares of Merck & Company, Inc. in a report on Wednesday, November 15th. BMO Capital Markets set a $70.00 price target on shares of Merck & Company, Inc. and gave the company a “buy” rating in a report on Wednesday, October 18th. Finally, Deutsche Bank AG lowered their price target on shares of Merck & Company, Inc. from $62.00 to $59.00 and set a “hold” rating for the company in a report on Friday. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $66.44.

In related news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total value of $281,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.25% of the company’s stock.

Shares of Merck & Company, Inc. (NYSE MRK) opened at $54.35 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. Merck & Company, Inc. has a 1 year low of $53.63 and a 1 year high of $66.80. The firm has a market cap of $148,073.14, a PE ratio of 13.97, a P/E/G ratio of 2.34 and a beta of 0.78.

Merck & Company, Inc. (NYSE:MRK) last posted its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.08. Merck & Company, Inc. had a net margin of 11.60% and a return on equity of 27.08%. The company had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. During the same period in the prior year, the company posted $1.07 EPS. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis. equities research analysts predict that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Swiss National Bank Grows Holdings in Merck & Company, Inc. (MRK)” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://transcriptdaily.com/2017/11/26/swiss-national-bank-grows-holdings-in-merck-company-inc-mrk.html.

Merck & Company, Inc. Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & Company, Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply